Contents 2 In the news 4 Review Article A practical education programme for rural Africa C Price, D Shandu, and G Gill 10 Review Article Editor Professor Geoff Gill The role of the pharmacist in the management of the hypertensive diabetic patient A Adeyemi Liverpool School of Tropical Medicine, and University Hospital, Aintree, UK 11 Review Article Consulting Editor Professor Sir George Alberti Senior Research Fellow, Imperial College London Past President, International Diabetes Federation Editorial Board Dr Ibrahim Sherif – Libya Prof Ken Huddle – South Africa Dr Kaushik Ramaiya – Tanzania Dr Nigel Unwin – UK/Switzerland Dr J C Mbanya – Cameroon Publisher Bryan Pearson Managing Editor and Production Penny Lang Advertisement Manager Jo Paul Business Manager Grant Docking ISSN 1468-6570 All contents are © 2008 FSG Communications Ltd Diabetic heart disease: risk factors and pathogenisis O A Busari, O T Olarewaju, and O G Opadijo 14 More news 15 Original Article Association between glycaemic control and erectile dysfunction amongst Nigerian diabetic patients B C Unadike, A Eregie, and A E Ohwovoriole 19 Original Article Glycaemic response to different preparations of yam in diabetic and non-diabetic Nigerians A K Jimoh, S O Adediran, S A Adebisi, A A Akande, J K Olarinoye, and A B Okesina 23 Original Article Does diabetic mastopathy exist in north-eastern Nigeria? A U Hamidu, M Alkali, and M A Abdul 24 Guidance for authors May 2008 May 2008 New drugs for diabetes In Europe recently, a new class of oral hypolycaemic agents (OHAs) have been released, working in an entirely different way from other drugs for type 2 diabetes. These operate by stimulating the incretin hormone systems. Incretins are hormones which are released from the small intestine in response to food intake, stimulating insulin release, inhibiting glucagon, and increasing gastric emptying. The effect is to lower blood glucose, without hypoglycaemia, and usually with weight loss rather than weight gain. The commonest incretin hormone is GLP–1 (glucagon-like peptide 1), and the drug exanetide is an agonist of this hormone. Exanetide has to be given subcutaneously, twice daily (bd), but the dose regimen is simple – 5 μg bd (initially, increasing to 10 μg bd after 1 month if there are no side-effects. There are no other dose titrations after that. Sitagliptin is an orally active drug that inhibits the enzyme which breaks down GLP–1, thus increasing its overall activity. Initital experience with these drugs appears positive. The lack of weight gain as a side-effect is particularly useful in the common problem of the overweight or obese, poorly controlled type 2 patient. Naturally, they are expensive, and it is likely to be some time before they are available to African doctors. Nevertheless, we at Diabetes International always feel that diabetes care workers in Africa should be kept aware of important advances in the specialty. Prof. Geoff Gill, Liverpool School of Tropical Medicine, Liverpool, UK Editor, Diabetes International Correspondence to: Diabetes International FSG Communications Ltd Vine House • Fair Green • Reach Cambridge CB25 0JD • UK Tel: +44 (0)1638 743633 Fax: +44 (0)1638 743998 Mera: Diabetes International 3